Related Experiment Video
Updated: Sep 26, 2026

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
Published on: November 4, 2018
Intravenous gene therapy for familial hypercholesterolemia using ligand-facilitated transfer of a liposome:LDL
M Shichiri1, A Tanaka, Y Hirata
1Department of Clinical and Molecular Endocrinology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan.
Insights
Familial hypercholesterolemia (FH) treatment shows promise with a novel gene therapy. Transferrin-facilitated liposomal delivery of LDLR cDNA reduced cholesterol in FH rabbits, offering a potential new therapeutic avenue.
Area of Science:
- Genetics
- Molecular Biology
- Cardiovascular Disease
Background:
- Familial hypercholesterolemia (FH) is a genetic disorder caused by LDLR gene mutations.
- Standard cholesterol-lowering treatments are often ineffective for FH patients.
- FH significantly increases the risk of coronary artery disease.
Purpose of the Study:
- To evaluate the efficacy of transferrin-facilitated intravenous gene therapy in an animal model of FH.
- To investigate the impact of LDLR gene delivery on plasma cholesterol levels.
- To assess the correlation between gene delivery and LDLR mRNA expression.
Main Methods:
- Utilized Watanabe Heritable Hyperlipidemic Rabbits (WHHL), an animal model for FH.
- Administered cationic liposome complexes containing rabbit LDLR cDNA via intravenous transfer.
- Facilitated gene delivery using transferrin.
- Measured plasma total and LDL cholesterol levels.
- Quantified LDLR mRNA transcripts in leukocytes.
Main Results:
- Intravenous treatment dose-dependently decreased plasma total and LDL cholesterol levels.
- Observed a positive correlation between treatment and increased LDLR mRNA transcripts in leukocytes.
- Demonstrated successful alleviation of hypercholesterolemia in WHHL rabbits.
Conclusions:
- Transferrin-facilitated intravenous gene delivery of LDLR cDNA is effective in reducing hypercholesterolemia.
- This approach shows potential as an adjunctive therapy for Familial hypercholesterolemia.
- Further research may lead to novel treatment strategies for FH.
Abstract:
Familial hypercholesterolemia (FH) is an autosomal dominant disorder because of a mutation in the low-density lipoprotein receptor (LDLR) gene. Although lowering plasma cholesterol decreases the risk of coronary artery disease, FH patients respond poorly to pharmacologic treatment. Transferrin-facilitated intravenous transfer of a cationic liposome rabbit LDLR cDNA complex alleviated hypercholesterolemia in Watanabe Heritable Hyperlipidemic Rabbits (WHHL), an animal model of FH. Intravenous treatment dose dependently decreased plasma total and LDL cholesterol levels, correlating with an increased level of LDLR mRNA transcripts in leukocytes. Transferrin-facilitated intravenous delivery of cationic liposome LDLR gene complexes could serve as an important adjunct therapy for the treatment of FH.
More Related Videos
Related Concept Videos
Gene Therapy
Pharmacogenomics: Identification of New Drug Targets
Receptor-mediated Endocytosis
Lipid-Lowering Drugs: Statins and Miscellaneous Agents

